⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

CLMT

Calumet, Inc.

Basic Materials · Specialty Chemicals

49.305USD

-0.0150 (-0.03%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Loading security description…
A first visit to a security takes a few seconds.

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on CLMT.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.

Calumet, Inc.

Ticker CLMT · NasdaqGS
Basic Materials »Research »
Classification Specialty Chemicals

Calumet, Inc. manufactures, formulates, and markets a slate of specialty branded products and renewable fuels in North America and internationally. It operates through Specialty Products and Solutions; Performance Brands; and Montana/Renewables segments. The Specialty Products and Solutions segment manufactures and markets various solvents, waxes, customized lubricating oils, white oils, petrolatums, gels, esters, and other products. The Montana/Renewables segment processes geographically advantaged renewable feedstocks into renewable diesel, aviation fuel, and renewable naphtha. This segment also engages in the process of Canadian crude oil into conventional gasoline, diesel, jet fuel, and specialty grades of asphalt. The Performance Brands segment blends, packages, and markets high performance products through Royal Purple, Bel-Ray, and TruFuel brands. It serves wholesale distributors and retail chains. Calumet, Inc. was founded in 1919 and is headquartered in Indianapolis, Indiana.

1)

Price Chart

GP »

Price

 

 

1M6MYTD1Y5Y
Close
Px/Chg 1D (USD)49.31 / -0.03%
52 Wk H (09/17/26)59.05
52 Wk L (11/20/25)18.22
YTD Change/%29.44 / 148.2%
Mkt Cap (USD)4.3B
Shrs Out/Float87.9M / 60.2M
SI/% of Float3.6M / 5.2%
Days to Cover2.4
2)

Estimates

EE »
Next Report11/06/26
P/E—
Est P/E 12/202615.41
T12M EPS (USD)-1.55
Est EPS3.20
Est PEG0.65
Analyst Target$55.80
3)

Dividend

DVD »
Ind Gross Yield0.0%
Ind Ann Dvd (USD)—
5Y Avg Yield12.0%
Cash 01/29/16 (USD)0.69
Payout Ratio0.0%
Ex-Dvd Date01/29/16
4)

Total Return

COMP »
1M-9.32%
3M+18.28%
6M+61.20%
1Y+146.67%
3Y+216.29%
5Y+345.84%
52W vs SPX+145.20% / +10.89%
Beta0.78
5)

Trading

HP »
Day Range48.32 - 50.00
Prev Close49.32
Volume1.2M
Avg Volume1.4M
50d Avg53.63
200d Avg37.78
Employees1,540
6)

Fundamentals snapshot

Reading the stored fundamentals…

Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.

6)

Fundamentals snapshot

Fundamentals snapshotValue 1 of 6 checks passed; Growth not enough data; Past performance 1 of 5 checks passed; Health 0 of 6 checks passed; Dividend no dividendValue1 of 6Growthn/aPast1 of 5Health0 of 6Dividendnone
  • Value1 of 6 checks passed

    Is the price low against peers, cash flow and analyst targets?

  • GrowthNot enough data

    Do analysts expect earnings and revenue to keep growing?

    Only 3 of 6 checks could be assessed because too few analysts cover it and there is no analyst coverage stored; 4 are needed.

  • Past performance1 of 5 checks passed

    Has the business grown and earned good returns on its filed numbers?

    1 of 6 checks could not be assessed (the figures they need are not meaningful here).

  • Health0 of 6 checks passed

    Can the balance sheet carry its debt?

  • DividendNo dividend

    Is the dividend decent, covered and steady?

    No dividend appears in the stored data, so this axis is left off the shape rather than drawn as zero.

An axis marked n/a has no vertex: it is left out of the shape rather than drawn as zero.

How this is scored

Each axis asks six plain questions of the stored data. A check that passes counts one. A check the stored data cannot answer is left out of the count, never counted as a fail, and an axis needs four answerable checks to show a result. Axes are never added together: there is no overall score. The thresholds are conventional rules of thumb and are blunt across sectors, so each check is listed with its rule and the figure it used.

Value

  1. P/E below peers

    Trailing P/E is positive and below the median of its peers: the companies in its industry if there are at least 5, else its sector if at least 10, else the whole market if at least 30, always in the same currency.

    Loss-making over the last twelve months, so there is no P/E to compare.

    ✕ Did not pass

  2. PEG ratio

    The PEG ratio is positive and at most 1.5.

    PEG 0.65.

    ✓ Passed

  3. EV/EBITDA below peers

    EV/EBITDA is positive and below the peer median, with peers chosen as for P/E. Not applied to financial companies.

    EV/EBITDA 82.1 against a peer median of 11.6 (16 USD companies in Specialty Chemicals).

    ✕ Did not pass

  4. Price/book below peers

    Price to book is positive and below the peer median, with peers chosen as for P/E.

    Book value is negative (liabilities exceed assets), so there is no price/book to compare.

    ✕ Did not pass

Statements: SEC filings, newest period 06/2026.

Peers: P/E against 13 USD companies in Specialty Chemicals; EV/EBITDA against 16 USD companies in Specialty Chemicals; price/book against 17 USD companies in Specialty Chemicals.

Rules of thumb applied to stored filings and quote data. Statements are as of the newest period shown above; multiples, analyst targets, estimates and yield come from a best-effort refresh and can lag by days. A count of plain checks, not a rating, a valuation or investment advice. Terms

  • Free cash flow yield

    Free cash flow is at least 4.5% of market cap, the risk-free rate used across this site. Not applied to financial companies.

    Free cash flow yield 1.3% against a 4.5% risk-free rate.

    ✕ Did not pass

  • Analyst target above price

    The mean analyst target is at least 15% above the last close, from at least 3 analysts. A published consensus, not a fair value.

    Mean analyst target above the last close by 13.2% (5 analysts).

    ✕ Did not pass

  • Growth

    1. Earnings growth, next year

      Consensus EPS for next fiscal year is at least 10% above this year's consensus, from at least 3 analysts.

      Only 1 analysts behind the estimate; 3 are needed.

      – Not assessed

    2. Earnings growth, this year

      Consensus EPS for this fiscal year is at least 10% above last year's figure on the same street basis, from at least 3 analysts.

      Only 1 analysts behind the estimate; 3 are needed.

      – Not assessed

    3. Revenue growth, next year

      Consensus revenue for next fiscal year is at least 5% above this year's consensus, from at least 3 analysts.

      Next year's revenue: consensus down 2.9% (6 analysts).

      ✕ Did not pass

    4. Revenue growth, this year

      Consensus revenue for this fiscal year is at least 5% above last year's reported revenue, from at least 3 analysts.

      This year's revenue: consensus up 23.0% (6 analysts).

      ✓ Passed

    5. Estimates rising

      More analysts raised than cut this year's EPS estimate over the last 90 days, with at least 2 revisions in all.

      No analyst estimates are stored for this security.

      – Not assessed

    6. Revenue growth, latest quarter

      Revenue in the latest quarter is at least 8% above the same quarter a year earlier.

      Latest-quarter revenue up 40.8% on a year earlier.

      ✓ Passed

    Past performance

    1. Earnings growth, multi-year

      Net income grew at least 5% a year over up to 5 fiscal years (at least 3 annual figures, positive at both ends).

      Net income was not positive in FY2025.

      ✕ Did not pass

    2. Earnings growth, last year

      Net income over the latest twelve months is above the twelve months before it, and positive.

      Net income was still a loss (twelve months to 06/2026).

      ✕ Did not pass

    3. Revenue growth, multi-year

      Revenue grew at least 3% a year over up to 5 fiscal years (at least 3 annual figures).

      Revenue fell 4.1% a year, FY2022 to FY2025.

      ✕ Did not pass

    4. Return on equity

      Return on equity is at least 15%: twelve-month net income over average equity. Not meaningful when equity is negative.

      Return on equity is not meaningful: equity is not positive.

      – Not assessed

    5. Return on assets

      Return on assets is at least 5%: twelve-month net income over average assets. Not applied to financial companies.

      Return on assets -4.9%: twelve-month net income over the average assets.

      ✕ Did not pass

    6. Cash earnings

      Operating cash flow over the latest twelve months is positive and at least net income. Not applied to financial companies.

      Operating cash flow was at or above net income over the last twelve months.

      ✓ Passed

    Health

    1. Current ratio

      Current assets are at least 1.0x current liabilities. Not applied to financial companies.

      Current ratio 0.8x.

      ✕ Did not pass

    2. Short-term assets cover long-term liabilities

      Current assets are at least the liabilities that fall due after a year (total liabilities less current liabilities). Not applied to financial companies.

      Current assets are 0.4x the liabilities due after a year.

      ✕ Did not pass

    3. Debt to equity

      Total debt is at most 100% of equity; no debt passes, negative equity with debt does not. Not applied to financial companies.

      Equity is negative while the company carries debt.

      ✕ Did not pass

    4. Net debt to EBITDA

      Net debt (total debt less cash) is at most 3.0x EBITDA; a net cash position passes. Not applied to financial companies.

      Net debt is 12.6x EBITDA.

      ✕ Did not pass

    5. Interest cover

      Operating income covers interest expense at least 3.0x; no debt passes. Not applied to financial companies.

      Operating income covers interest 0.2x.

      ✕ Did not pass

    6. Cash flow to debt

      Operating cash flow is at least 20% of total debt; no debt passes. Not applied to financial companies.

      Operating cash flow is 6.2% of total debt.

      ✕ Did not pass

    Dividend

    1. Dividend yield

      The dividend yield is at least 2%.

      No dividend appears in the stored data.

      – Not assessed

    2. Payout ratio

      Dividends paid are at most 75% of net income. Not applied to real estate companies, whose net income is after depreciation.

      No dividend appears in the stored data.

      – Not assessed

    3. Free cash flow cover

      Free cash flow covers the dividends paid at least 1.0x. Not applied to financial companies.

      No dividend appears in the stored data.

      – Not assessed

    4. Paid every year

      A dividend was paid in every one of the last 4 to 8 fiscal years stored (consecutive years, all present). A year missing from the filings data is not read as no dividend, so a gap makes this not assessed.

      No dividend appears in the stored data.

      – Not assessed

    5. No cuts

      Total dividends paid never fell by more than 20% from one fiscal year to the next in that window.

      No dividend appears in the stored data.

      – Not assessed

    6. Growing dividend

      Total dividends paid grew at least 3% a year across that window. The total, not per share: no per-share dividend history is stored.

      No dividend appears in the stored data.

      – Not assessed